Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report

Sohayb Faleh; Tanya Odisho; Florence Lebel-Guay; Mikaël L. Soucisse; Jose Ferreira; Sara V. Soldera; Lucas Sideris

doi:10.12659/AJCR.949777

09 November 2025 : Case report Canada

Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report

Unusual clinical course, Unusual or unexpected effect of treatment

Sohayb Faleh^{ABCDEF 1,2,3}, Tanya Odisho^{BDEF 3}, Florence Lebel-Guay^{BEF 1}, Mikaël L. Soucisse

^{ABD 1}, Jose Ferreira^{BD 4}, Sara V. Soldera

^{ABCDEF 5}, Lucas Sideris^{ABCDEF 1*}

DOI: 10.12659/AJCR.949777

Am J Case Rep 2025; 26:e949777

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Immunohistochemistry studies demonstrating positivity for MTAP (A), BAP-1 (B), Calretinin (C), WT1 (D), D2–40 (E), and cytokeratin 5/6 (F), with negative staining for BerEp4 (G), consistent with peritoneal mesothelioma.

Back to the Article

Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report

Your Privacy